

CHILTON HOSPITAL

INPATIENT ANTIBIOTIC SUSCEPTIBILITY OF FREQUENTLY ENCOUNTERED PATHOGENS

JANUARY - DECEMBER
2010/2011/2012

FORMULARY INTRAVENOUS ANTIBIOTICS

Pencillins	Average Dose	M	P	A	R
Ampicillin	500 mg-2 gm q4h				
Penicillin G Potassium	1-4 mU q4h				
Nafcillin	1-2 gm q4-6h				
Ampicillin/Sulbactam	1.5-3 gm q6h				
Piperacillin/Tazobactam	3.375 gm q6h				
Imipenem/Cilastatin	500 mg q6h				
Ertapenem	1 g IV q24h				
Meropenem	0.5-2 gm IV q8h				
Aminoglycosides					
Amikacin	7.5 mg/kg q12h				
Gentamicin	2 mg/kg q12h				
Tobramycin	2 mg/kg q12h				
Cephalosporins					
Cefazolin	1 gm q8h				
Cefoxitin	2 gm q6h				
Cefuroxime	750 mg-1.5 gm q8h				
Ceftriaxone	1 gm q24h				
Cefotaxime	1 gm q8h				
Cefepime	1-2 gm q8-24h				
Macrolides					
Erythromycin	500 mg-1 gm q6h				
Azithromycin	250-500 mg q24h				
Fluoroquinolones					
Ciprofloxacin	200-400 mg q12h				
Levofloxacin	250-750 mg q24h				
Antifungal					
Fluconazole	100-400 mg q24h				
Amphotericin B	0.25-1 mg/kg/day				
Micafungin	100 mg/day				
Miscellaneous abx.					
Aztreonam	1-2 gm q8h				
Clindamycin	600 mg q8h				
Vancomycin	1 gm q12h				
Metronidazole	500 mg q8h				
Doxycycline	100 mg q12h				
SMZ/TMP	10-15 mg (TMP)/kg/day In 2 - 4 divided doses				
Linezolid	600 mg IV q12h				
Tigecycline	50 mg IV q12h				
Daptomycin	6-8 mg/kg q24h				

FORMULARY ORAL ANTIBIOTICS

Pencillins	Average Dose	M	P	A	R
Penicillin	250-500 mg q6h				
Amoxicillin	250-500 mg q8h				
Amoxicillin/ clavulanate	500-875 mg q12h				
Dicloxacillin	250-500 mg q6h				
Cephalosporins					
Cephalexin	250-500 mg q6h				
Cefuroxime axetil	250 mg-500 mg q12h				
Cefaclor	250 mg q8h				
Fluoroquinolones					
Ciprofloxacin	250-750 mg q12H				
Levofloxacin	250-750 mg q24h				
Tetracyclines					
Doxycycline	100 mg q12h				
Tetracycline	250-500 mg q6h				
Macrolides					
Erythromycin	250-500 mg q6h				
Azithromycin	250-500 mg q24h				
Antifungals					
Fluconazole	100-200 mg q2-4h				
Nystatin susp.	5 mL 5 x per day				
Voriconazole	200 mg q12h				
Misc.					
SMZ/TMP	800/160 mg q12h				
Nitrofurantoin	100 mg q12h				
Clindamycin	300 mg q8h				
Metronidazole	250-500 mg q8h				
Vancomycin	125 mg-250 mg q6h				
Linezolid	600 mg q12h				

M - MRSA Coverage
P - *Pseudomonas aeruginosa* coverage
A - anaerobe coverage
R - restricted antibiotic
+ = Usually effective clinically or >60% susceptible
± = Clinical trials lacking or 30 - 60% susceptible

ANTIMICROBIAL SUSCEPTIBILITY REPORT

2010/2011/2012

Essam A. Ahmed, M.D.
Director Pathology
Marilyn Rosen, BS, MT
Microbiology Supervisor

Numbers are Percentage Susceptible

Kanan Shah, PharmD
Infectious Disease
Natalie Erichsen, PharmD
Critical Care

ORGANISM (# of isolates in 2012)	Amikacin	Ampicillin	Amoxicillin/Clav (Augmentin)	Cefazolin (Ancef)	Cefoxitin (Mefoxin)	Cefepime (Maxipime)	Ceftriaxone (Rocephin)	Ciprofloxacin (Cipro)	Gentamicin	Ertapenem (Invanz)	Imipenem/cilas- tatin (Primaxin)	Levofloxacin (Levaquin)	Piperacillin/ Tazobactam (Zosyn)	Tigecycline (Tygacil)	Tobramycin	Nitrofurantoin (Macrobid)	TMP/SMX (Bactrim)	Nafcillin	Daptomycin (Cubicin)	Linezolid (Zyvox)	Vancomycin
Gram Negative																					
<i>E. coli</i> (945) ESBL-9%	100/100/100	52/52/47	79/82/77	85/84/82	88/88/85	93/92/91	92/91/90	69/72/71	90/90/90	-100/100	100/100/100	69/72/71	95/97/100	100/100/100	90/90/89	94/93/89	77/76/74				
<i>Kleb. pneumo.</i> (286) ESBL-5%	92/92/91		88/89/87	83/85/85	88/87/88	87/88/88	87/88/88	85/87/87	92/92/92	-92/92	93/92/92	85/86/87	87/90/97	95/93/100	87/89/88		83/85/85				
<i>P. aeruginosa</i> (21)	97/96/99					87/89/91		63/70/77	78/77/90		89/85/91	57/67/71	90/91/-		96/95/93						
<i>Proteus mirabilis</i> (226)	100/100/100		83/92/100	74/79/73	91/93/86	75/80/76	75/80/76	56/64/58	92/94/92	-100/100	98/96/100	62/66/62	98/99/-		97/98/94		79/87/82				
<i>E. cloacae</i> (61)	92/100/100					95/100/97	76/88/88	84/90/96	95/98/96	-98/100	97/100/98	84/92/96	79/81/-		94/98/96		87/92/86				
<i>Serratia Mar.</i> (35)	98/98/100					98/95/100	96/95/94	88/95/91	98/98/100	-100/100	98/100/100	88/92/91	84/81/-		96/95/86		98/93/-				
<i>Morganella</i> (34)	100/100/100					94/100/97	94/100/97	52/64/55	76/88/82		96/93/100	54/70/55	68/100/-		96/97/97		44/70/55				
<i>Citrobacter spp.</i> (50)	-1/100	-100/-	-100/100			-98/100	-96/100	-96/100	-96/100	-100/100	-100/100	-96/100	-92/-	-99/100	-96/100	-78/64					
<i>Ac. baumannii</i> (21)	97/100/-					42/47/48		33/47/29	48/53/62		45/58/67	36/47/29	45/27/-	61/65/-	70/79/71						
Gram Positive																					
<i>Staph. aureus</i> (645)								53/51/49				53/53/50		100/100/100			99/99/97	49/53/52	-1/100	100/100/100	100/100/100
<i>Coag. Neg. Staph.</i> (191)																		43/44/62		100/100/100	100/100/100
<i>E. faecalis</i> (347)		96/98/99												100/100/100		97/100/99			-100/100	100/100/100	97/95/92
<i>E. faecium</i> (57)														100/100/100					100/100/100	100/100/100	26/19/19
<i>Strep. pneumo.</i> (11)			-1/100				85/94/100*					97/94/100							100/100/100	-1/100	

This antibiogram is provided as a tool for guiding initial therapy. Organisms which exhibit >80% sensitivity to the antibiotic would be expected to be sensitive to appropriate treatment. The number of organisms tested may include duplicate isolates from the same patient after 30 days. *Due to the FDA recall of Vitek cards, the microbiology lab manually dropped Pip/Tazo only on positive blood cultures or organisms positive for ESBL. The percent susceptible for both organisms is based on a lower number of isolates (*E. coli* -62 isolates, *Klebsiella pneumoniae*-29 isolates)

* = Meningitis; ** = Non-Meningitis